Back to Search
Start Over
Outcomes of first subsequent taxane (FST) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel intensification (DI) for metastatic castration-sensitive prostate cancer (mCSPC).
- Source :
- Journal of Clinical Oncology; 2/21/2023 Supplement, Vol. 41, p72-72, 1p
- Publication Year :
- 2023
Details
- Language :
- English
- ISSN :
- 0732183X
- Volume :
- 41
- Database :
- Supplemental Index
- Journal :
- Journal of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 162006964
- Full Text :
- https://doi.org/10.1200/JCO.2023.41.6_suppl.72